JPRN-jRCT1090220258招募中Unknown
Clinical effects of everolimus in the ubjects with tuberous sclerosis. - Clinical effects of everolimus in the subjects with ASD
Kunio Yui0 个研究点目标入组 20 人开始时间: 2016年8月2日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- >= 5age old 至 <= 30age old（—）
- 性别
- All
入选标准
- •Individuals with autism spectrum disorders in TSC
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Efficacy and Safety of Everolimus in Patients with Unresectable or Metastatic Renal Cell Carcinomarenal cell carcinomaJPRN-UMIN000008769Tokyo Afinitor Clinical Trial Group - RCC(TACT-R)120
尚未招募
2 期
Efficacy and Safety of Everolimus in Patients with Non-Clear Cell Renal Cell Carcinomaon-clear cell renal cell carcinomaJPRN-UMIN000006248Yamaguchi University Graduate School of Medicine , Department of Urology10
进行中（未招募）
1 期
Introduction of everolimus is associated with a reduction in the dosage of calcineurine-inhibitors in patients with a pulmonary graft who suffer from a notable chronic renal insuffisance.Patient who received a pulmonary transplant and who show notable renale insuffisance (DFG < 50ml/min/1.73m²) which has been progressive over the last two years or chronical renal insuffisance which progresses fast (a los of >50% DGF in 3 months) and isotopical glomerural filtration < 45 ml/min.EUCTR2006-001945-32-BEB Erasme15
招募中
2 期
Efficacy of 0.05%topical everolimus in the treatment of adenoma sebaceum in tuberous sclerosisadenoma sebaceumTCTR20180820002Dermatology division, Department of internal medicine, King Chulalongkorn Memorial Hospital15
尚未招募
不适用
In-vivo Bioequivalence Test of NEORAPA® tablet with brand drugs (AFINITOR® 10mg Novartis).In this study, the disease is not examined. Subject bioequivalence test and reference tablets Everolimus studied..IRCT20200105046010N24ABIDI Pharmaceutical Company24